Presbyopia lens launch

Article

Oculentis will present its presbyopia correcting LENTIS Mplus IOL at DOC 2009 in Nuremberg to an expert audience. It claims the lens features a completely new approach in multi-focal lens technology.

Oculentis will present its presbyopia correcting LENTIS Mplus IOL at DOC 2009 in Nuremberg to an expert audience. It claims the lens features a completely new approach in multi-focal lens technology.

The main feature of this multifocal lens is its aspheric multi-curve design comprising a segment shaped near-vision section characterized by seamless transitions between the near and far vision zones.

Various benefits for the patient are said to result from this innovative design. In particular, reflections and image jumps as usually in twilight light conditions or in central headlight glare conditions will no longer occur. Furthermore the MIOL is pupil independent, offers true +3 D addition and ensures a minimal loss of light.

A multi-center study conducted under the leadership of Professor G. U. Auffarth of Heidelberg University Eye Clinic analyzed the results obtained by the implantation of the lens in 114 eyes of 69 patients (mean age: 68 ± 12 years). Oculentis says this confirmed the functional outcomes achieved with the MIOL as well as a very high degree of patient satisfaction. No complications were seen in both, unilateral and bilateral implantation. Mean IOL power came to 21.00 ± 2.01 D Three months after surgery, a best corrected distance visual acuity of 0.01 ± 0.14 logMAR was measured. Uncorrected near visual acuity came to 0.08 ± 0.17 logMAR.

Using the computer-controlled SML technology, each LENTIS Mplus IOL will be customized to the special needs of the individual patient and is made from the well-proved HydroSmart material.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.